Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer's Mylotarg Finally Gets CHMP Nod But No New Indication For Sutent

Executive Summary

The EMA is finally set to approve Pfizer's targeted anticancer Mylotarg for use in acute myeloid leukemia. The company also received opinions for Bosulif and Sutent. 


Related Content

More Good News For AML As Pfizer And AbbVie/Roche Drugs Get FDA Okay
More New EU Drug Approvals Bring Total For Year To 14
Six New Drugs Get EMA Nod, Radius and Portola To Fight Rejections
Clovis Confident, Portola Not: CHMP Decides On EU Marketing Applications
EU Moves To RATIFY Novartis' Rydapt for AML
Mylotarg, Event-Free Survival Endpoint Both Get FDA Panel Endorsement
Pfizer withdraws leukaemia drug Mylotarg from US market on safety and efficacy concerns


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts